X0306 4 2020-05-19 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001742587 Sinha Uma C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 0 1 0 0 Chief Scientific Officer Common Stock 2020-05-19 4 A 0 1523 0.00 A 15523 D Stock Option (Right to Buy) 1.25 2020-05-19 4 A 0 5366 0.00 A 2020-05-19 2027-11-15 Common Stock 5366 5366 D Stock Option (Right to Buy) 0.16 2020-05-19 4 A 0 49361 0.00 A 2029-05-23 Common Stock 49361 49361 D Stock Option (Right to Buy) 0.34 2020-05-19 4 A 0 49765 0.00 A 2029-07-14 Common Stock 49765 49765 D Stock Option (Right to Buy) 3.35 2020-05-19 4 A 0 3022 0.00 A 2020-05-19 2029-09-30 Common Stock 3022 3022 D The shares were acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in privately-held subsidiaries of the Issuer (each, a "Subsidiary" and collectively, the "Subsidiaries"). The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. 24,930 shares subject to the stock option were vested and exercisable as of the date of acquisition, 1,558 shares shall vest and become exercisable on June 1, 2020, and 22,873 shares shall vest and become exercisable in monthly installments over the next 15 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. 25,134 shares subject to the stock option were vested and exercisable as of the date of acquisition, 1,571 shares shall vest and become exercisable on June 1, 2020, and 23,060 shares shall vest and become exercisable in monthly installments over the next 15 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. /s/ Tara Condon, Attorney-in-Fact 2020-05-21